Michael R. McDonnell serves as the Executive Vice President and Chief Financial Officer at Biogen Inc., a leading biotechnology company focused on developing therapies for neurological and neurodegenerative diseases. With a robust background in finance and a proven track record in the biotechnology sector, McDonnell has been instrumental in steering Biogen's financial strategies and operations. He joined Biogen in 2018 and has since played a pivotal role in the company's growth and financial stability. Before joining Biogen, McDonnell held various senior financial positions at other prominent companies. He served as the Senior Vice President and Chief Financial Officer at Shire Pharmaceuticals, where he was responsible for overseeing the company's global financial operations and played a key role in several strategic acquisitions and partnerships. His experience also extends to other sectors, having worked at Ernst & Young LLP and PepsiCo, Inc., where he honed his skills in financial planning and analysis. At Biogen, McDonnell's responsibilities include managing the company's financial planning, budgeting, and investor relations, ensuring that Biogen remains at the forefront of innovation while maintaining financial health. Under McDonnell's leadership, Biogen has continued to invest in research and development, leading to the successful launch of new therapies and the expansion of its product portfolio. His strategic financial oversight has been crucial in navigating the complex landscape of the biotechnology industry, enabling Biogen to achieve sustainable growth and deliver value to its shareholders. McDonnell's commitment to excellence and his deep understanding of the financial aspects of the biotech sector make him a vital asset to Biogen and its mission to transform the lives of patients worldwide.